Altimmune annual operating margin
2010
2011
2016
2017
2018
2019
2020
2021
2023
2024
2025
Altimmune's operating margin was −230,460.98% for fiscal 2025.
View full Altimmune company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −230,460.98% | +285399.02 pp |
| 2024 | 2024-12-31 | −515,860.00% | −493341.46 pp |
| 2023 | 2023-12-31 | −22,518.54% | −20321.13 pp |
| 2021 | 2021-12-31 | −2,197.42% | −1527.92 pp |
| 2020 | 2020-12-31 | −669.50% | −299.50 pp |
| 2019 | 2019-12-31 | −370.00% | +44.62 pp |
| 2018 | 2018-12-31 | −414.61% | +70.06 pp |
| 2017 | 2017-12-31 | −484.67% | −141.93 pp |
| 2016 | 2016-12-31 | −342.74% | −294.42 pp |
| 2011 | 2011-12-31 | −48.32% | +63.87 pp |
| 2010 | 2010-12-31 | −112.19% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | −111,126.92% | +386193.08 pp |
| Q3 2025 | 2025-09-30 | −417,180.00% | +78160.00 pp |
| Q2 2025 | 2025-06-30 | −458,440.00% | +76460.00 pp |
| Q1 2025 | 2025-03-31 | −436,300.00% | +99580.00 pp |
| Q4 2024 | 2024-12-31 | −497,320.00% | −406447.03 pp |
| Q3 2024 | 2024-09-30 | −495,340.00% | −489113.48 pp |
| Q2 2024 | 2024-06-30 | −534,900.00% | −234783.33 pp |
| Q1 2024 | 2024-03-31 | −535,880.00% | −432265.71 pp |
| Q4 2023 | 2023-12-31 | −90,872.97% | +1146727.03 pp |
| Q3 2023 | 2023-09-30 | −6,226.52% | +248710.98 pp |
| Q2 2023 | 2023-06-30 | −300,116.67% | −239182.29 pp |
| Q1 2023 | 2023-03-31 | −103,614.29% | −102882.45 pp |
| Q3 2022 | 2022-09-30 | −1,237,600.00% | −1216584.81 pp |
| Q2 2022 | 2022-06-30 | −254,937.50% | −236788.59 pp |
| Q1 2022 | 2022-03-31 | −60,934.38% | −59160.99 pp |
| Q4 2021 | 2021-12-31 | −731.84% | −267.03 pp |
| Q3 2021 | 2021-09-30 | −21,015.19% | −20391.49 pp |
| Q2 2021 | 2021-06-30 | −18,148.91% | −15596.65 pp |
| Q1 2021 | 2021-03-31 | −1,773.39% | −1443.17 pp |
| Q4 2020 | 2020-12-31 | −464.81% | +284.07 pp |
| Q3 2020 | 2020-09-30 | −623.70% | +1126.89 pp |
| Q2 2020 | 2020-06-30 | −2,552.25% | −2333.87 pp |
| Q1 2020 | 2020-03-31 | −330.22% | −251.43 pp |
| Q4 2019 | 2019-12-31 | −748.89% | +307.49 pp |
| Q3 2019 | 2019-09-30 | −1,750.58% | −1596.54 pp |
| Q2 2019 | 2019-06-30 | −218.38% | +6.51 pp |
| Q1 2019 | 2019-03-31 | −78.78% | +143.98 pp |
| Q4 2018 | 2018-12-31 | −1,056.38% | −609.06 pp |
| Q3 2018 | 2018-09-30 | −154.04% | +520.02 pp |
| Q2 2018 | 2018-06-30 | −224.89% | −92.85 pp |
| Q1 2018 | 2018-03-31 | −222.76% | +1285.08 pp |
| Q4 2017 | 2017-12-31 | −447.32% | +84.23 pp |
| Q3 2017 | 2017-09-30 | −674.06% | −459.28 pp |
| Q2 2017 | 2017-06-30 | −132.04% | — |
| Q1 2017 | 2017-03-31 | −1,507.85% | — |
| Q3 2016 | 2016-09-30 | −531.56% | — |
| Q2 2016 | 2016-06-30 | −214.78% | — |
Over the last five reported fiscal years, Altimmune's operating margin decreased from −370.00% to −230,460.98%, a change of −230090.98 percentage points. The latest reported quarter, Q4 2025, shows −111,126.92%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Altimmune filings at SEC.gov ↗